Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.

Key Findings

• ●Avapritinib induced 30% molecular response (KIT D816V undetectable) in AdvSM
• ●Deep responses across ASM, SM-AHN, and MCL subtypes

Referenced in (1 disease)

1. passsource metadataJun 1, 2026, 04:40 PMby pubmed-api

   Identifier corrected: prior entry (pmid-35926117) had a wrong PMID/DOI pointing to an unrelated paper; re-resolved by title to this record via PubMed/Crossref.

   tools: pubmed.esummary, crossref.works